← All trials
NCT06213649
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2024
- Primary completion
- Jul 31, 2028
- Completion date
- Jul 31, 2028
- First posted
- Jan 19, 2024
- Last posted
- Oct 4, 2024
- Enrollment
- 232
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Federal University of Sao PauloCollaborator
- University of FloridaCollaborator
- University of California, Los AngelesCollaborator
- University of IowaCollaborator
- Aravind Eye HospitalCollaborator
- Columbia UniversityCollaborator
- University of California, San FranciscoSponsor investigator
- University of MichiganCollaborator
- University of PennsylvaniaCollaborator
- National Eye Institute (NEI)Collaborator
- Johns Hopkins UniversityCollaborator
- University of Illinois at ChicagoCollaborator
- University of California, San FranciscoOfficial
- University of LondonCollaborator
- Oregon Health and Science UniversityCollaborator
- University of MiamiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.